| Name | Title | Contact Details |
|---|---|---|
Dani Markus |
Vice President of Payer Products and Clinical Programs | Profile |
Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The resulting, new therapeutic creates a more targeted molecule with the goal of improving treatment outcomes and improving compliance with treatment regimens. Our initial development areas are in oncology and infectious disease.
Amerigen Pharmaceuticals Inc is a East Brunswick, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Infinity Pharmaceuticals is an innovative cancer drug discovery and development company that leverages its strength in small molecule drug technologies to bring important new medicines to patients.
Corden Pharma Colorado is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.